[Skip to the reading](/semaglutide#reading)

[Peptide Therapy News](/)

[Regulatory](/regulatory) [Research](/research)

[Archive](/#event-index) [About](/about)

Source review through 27 October 2026 · Event dates appear with reports

[Home](/) / Semaglutide

# Who semaglutide’s heart-risk approval covers

The March 2024 decision was about fewer serious heart problems in a particular group of adults. The group is as important as the headline.

## Who the approval was for

Event · 8 March 2024

FDA announcement · 8 March 2024

![An older adult’s upper chest with a healed midline scar, partly visible above a casual shirt.](/press-desk-66428b6910dc/semaglutide.webp)

Illustration: a history of heart disease, not a semaglutide result.

### What happened

On 8 March 2024, FDA [expanded the approved use of semaglutide, sold as Wegovy](https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or). The decision covered reducing the risk of cardiovascular death, heart attack and stroke in adults with established heart and blood-vessel disease who also had overweight or obesity.

An approved use is sometimes called an indication. This one also specified reduced-calorie eating and increased physical activity. It wasn’t a blanket claim of heart protection for everyone taking semaglutide.

### What it means

The decision gave this group another reason a clinician might consider the medicine. It didn’t give every semaglutide preparation the same approval. The product and the approved use still matter, even when the ingredient name is familiar.

The trial behind the decision enrolled adults without diabetes. They already had cardiovascular disease and overweight or obesity. Someone with a different health history may have a different balance of possible benefits and risks.

## What “lower risk” looked like

In the [trial behind the approval](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b), 6.5% of people receiving semaglutide had a cardiovascular death, heart attack or stroke, compared with 8% receiving placebo. Here, placebo means the comparison group’s treatment had no active drug. Follow-up averaged a little over three years.

The trial reported a 20% relative reduction; the gap in actual event rates was 1.5 percentage points. Both help put the benefit in perspective. Some people in each group still had a serious cardiovascular event.

## The warnings still matter

Semaglutide’s label has a boxed warning, FDA’s strongest kind, about thyroid C-cell tumors seen in animals. It’s unknown whether that risk applies to humans. The label rules it out for people with a personal or family history of medullary thyroid cancer, or multiple endocrine neoplasia type 2, a rare inherited condition.

Nausea, vomiting, diarrhea and constipation were common in weight-loss trials. The label also warns about pancreatitis, inflammation of the pancreas, and gallbladder problems. The [prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b) is the fuller safety reference.

The [February 2025 shortage decision](/regulatory#shortage-record) concerned national supplies of semaglutide injections. It didn’t extend this heart-risk approval to compounded semaglutide, which is not FDA-approved. A licensed U.S. clinician can assess whether an approved medicine fits someone’s health needs.

## On this page

- [Who the approval was for](/semaglutide#heart-decision)

- [What “lower risk” looked like](/semaglutide#outcomes)

- [The warnings still matter](/semaglutide#safety)

Source review 27 October 2026

[Open the source desk](/references) [Follow the event dates](/#event-index)

Peptide Therapy News is a guide for reading the record, not a clinic, pharmacy or seller.

© 2026 Peptide Therapy News

[References](/references) [About](/about) [Contact](/contact) [Event index](/#event-index)